Alterations in Serum Lipids and Lipoproteins Induced by Neoadjuvant Chemotherapy in Patients with Osteosarcoma around the Knee Joint: A Retrospective Analysis

Abstract

Objective

To investigate the serum lipid profiles of patients with localized osteosarcoma around the knee joint before and after neoadjuvant chemotherapy.

Methods

After retrospectively screening the data of 742 patients between January 2007 and July 2020, 50 patients aged 13 to 39 years with Enneking stage II disease were included in the study. Serum lipid levels, including total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), lipoprotein-α [Lp(a)], and apolipoprotein A1, B, and E (ApoA1, ApoB, and ApoE), and clinicopathological characteristics were collected before and after neoadjuvant chemotherapy.

Results

The mean levels of TC, TG, and ApoB were significantly increased following neoadjuvant chemotherapy (16%, 38%, and 20%, respectively, vs. pretreatment values; P<0.01). The mean levels of LDL-C and ApoE were also 19% and 16% higher, respectively (P<0.05). No correlation was found between the pretreatment lipid profile and the histologic response to chemotherapy. An increase in Lp(a) was strongly correlated with the Ki-67 index (R=0.31, P=0.023). Moreover, a trend toward longer disease-free survival (DFS) was observed in patients with decreased TG and increased LDL-C following chemotherapy, although this difference was not statistically significant (P=0.23 and P=0.24, respectively).

Conclusion

Significant elevations in serum lipids were observed after neoadjuvant chemotherapy in patients with localized osteosarcoma. There was no prognostic significance of pretreatment serum lipid levels on histologic response to neoadjuvant chemotherapy. The scale of increase in serum Lp(a) might have a potential prognostic role in osteosarcoma. Patients with increased LDL-C or reduced TG after chemotherapy seem to exhibit a trend toward favorable DFS.

References

[1] Picci P. Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis, 2007, 2: 6

[2] Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin North Am, 1997, 44(4): 973-989

[3] Yamamoto N, Tsuchiya H. Chemotherapy for osteosarcoma–Where does it come from? What is it? Where is it going?. Expert Opin Pharmacother, 2013, 14(16): 2183-2193

[4] Jaffe N. Historical perspective on the introduction and use of chemotherapy for the treatment of osteosarcoma. Adv Exp Med Biol, 2014, 804: 1-30

[5] Gill J, Gorlick R. Advancing therapy for osteosarcoma. Nat Rev Clin Oncol, 2021, 18(10): 609-624

[6] Bramer JA, van Linge JH, Grimer RJ, et al.. Prognostic factors in localized extremity osteosarcoma: a systematic review. Eur J Surg Oncol, 2009, 35(10): 1030-1036

[7] Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis, 2016, 5: e189

[8] Visweswaran M, Arfuso F, Warrier S, et al.. Aberrant lipid metabolism as an emerging therapeutic strategy to target cancer stem cells. Stem Cells, 2020, 38(1): 6-14

[9] Kushwaha P, Wolfgang MJ, Riddle RC. Fatty acid metabolism by the osteoblast. Bone, 2018, 115: 8-14

[10] Alexopoulos CG, Pournaras S, Vaslamatzis M, et al.. Changes in serum lipids and lipoproteins in cancer patients during chemotherapy. Cancer Chemother Pharmacol, 1992, 30(5): 412-416

[11] Fernandes A, Messias MCF, Duarte GHB, et al.. Plasma Lipid Profile Reveals Plasmalogens as Potential Biomarkers for Colon Cancer Screening. Metabolites, 2020, 10(6): 262

[12] Melichar B, Kalabova H, Krcmova L, et al.. Serum homocysteine, cholesterol, retinol, alpha-tocopherol, glycosylated hemoglobin and inflammatory response during therapy with bevacizumab, oxaliplatin, 5-fluorouracil and leucovorin. Anticancer Res, 2009, 29(11): 4813-4820

[13] Qu F, Chen R, Peng Y, et al.. Assessment of the Predictive Role of Serum Lipid Profiles in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. J Breast Cancer, 2020, 23(3): 246-258

[14] Rodrigues Dos Santos C, Fonseca I, Dias S, et al.. Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression. BMC Cancer, 2014, 14: 132

[15] Rzymowska J. Effect of cytotoxic chemotherapy on serum lipid levels in breast cancer patients. Pathobiology, 1999, 67(3): 129-132

[16] Saarto T, Blomqvist C, Ehnholm C, et al.. Effects of chemotherapy-induced castration on serum lipids and apoproteins in premenopausal women with node-positive breast cancer. J Clin Endocrinol Metab, 1996, 81(12): 4453-4457

[17] Sharma M, Tuaine J, McLaren B, et al.. Chemotherapy Agents Alter Plasma Lipids in Breast Cancer Patients and Show Differential Effects on Lipid Metabolism Genes in Liver Cells. PLoS One, 2016, 11(1): e0148049

[18] Stathopoulos GP, Stergiou GS, Perrea-Kostarelis DN, et al.. Influence of 5-fluorouracil on serum lipids. Acta Oncol, 1995, 34(2): 253-256

[19] Tian W, Yao Y, Fan G, et al.. Changes in lipid profiles during and after (neo)adjuvant chemotherapy in women with early-stage breast cancer: A retrospective study. PLoS One, 2019, 14(8): e0221866

[20] Wang Y, Wang ZQ, Wang FH, et al.. Predictive value of chemotherapy-related high-density lipoprotein cholesterol (HDL) elevation in patients with colorectal cancer receiving adjuvant chemotherapy: an exploratory analysis of 851 cases. Oncotarget, 2016, 7(35): 57290-57300

[21] Yeo W, Mo FKF, Pang E, et al.. Profiles of lipids, blood pressure and weight changes among premenopausal Chinese breast cancer patients after adjuvant chemotherapy. BMC Womens Health, 2017, 17(1): 55

[22] Li X, Liu ZL, Wu YT, et al.. Status of lipid and lipoprotein in female breast cancer patients at initial diagnosis and during chemotherapy. Lipids Health Dis, 2018, 17(1): 91

[23] Lewis IJ, Nooij MA, Whelan J, et al.. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst, 2007, 99(2): 112-128

[24] Meyers PA, Schwartz CL, Krailo M, et al.. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol, 2005, 23(9): 2004-2011

[25] Bielack SS, Kempf-Bielack B, Delling G, et al.. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol, 2002, 20(3): 776-790

[26] Ganjali S, Ricciuti B, Pirro M, et al.. High-Density Lipoprotein Components and Functionality in Cancer: State-of-the-Art. Trends Endocrinol Metab, 2019, 30(1): 12-24

[27] Guijarro MV, Ghivizzani SC, Gibbs CP. Animal models in osteosarcoma. Front Oncol, 2014, 4: 189

[28] Leeper H, Viall A, Ruaux C, et al.. Preliminary evaluation of serum total cholesterol concentrations in dogs with osteosarcoma. J Small Anim Pract, 2017, 58(10): 562-569

[29] Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res, 1986, 204: 9-24

[30] Picci P, Bacci G, Campanacci M, et al.. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer, 1985, 56(7): 1515-1521

[31] Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med, 1977, 101(1): 14-18

[32] Wolf RE, Enneking WF. The staging and surgery of musculoskeletal neoplasms. Orthop Clin North Am, 1996, 27(3): 473-481

[33] Balaban S, Lee LS, Schreuder M, et al.. Obesity and cancer progression: is there a role of fatty acid metabolism?. Biomed Res Int, 2015, 2015: 274585

[34] Saavedra-Garcéa P, Nichols K, Mahmud Z, et al.. Unravelling the role of fatty acid metabolism in cancer through the FOXO3-FOXM1 axis. Mol Cell Endocrinol, 2018, 462: 82-92 Pt B

[35] Pakiet A, Kobiela J, Stepnowski P, et al.. Changes in lipids composition and metabolism in colorectal cancer: a review. Lipids Health Dis, 2019, 18(1): 29

[36] Lofterod T, Mortensen ES, Nalwoga H, et al.. Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes. BMC Cancer, 2018, 18(1): 654

[37] Molendijk J, Robinson H, Djuric Z, et al.. Lipid mechanisms in hallmarks of cancer. Mol Omics, 2020, 16(1): 6-18

[38] Mok EHK, Lee TKW. The Pivotal Role of the Dysregulation of Cholesterol Homeostasis in Cancer: Implications for Therapeutic Targets. Cancers (Basel), 2020, 12(6): 1410

[39] Menon SS, Guruvayoorappan C, Sakthivel KM, et al.. Ki-67 protein as a tumour proliferation marker. Clin Chim Acta, 2019, 491: 39-45

[40] Hernández-Rodréguez NA, Correa E, Sotelo R, et al.. Ki-67: a proliferative marker that may predict pulmonary metastases and mortality of primary osteosarcoma. Cancer Detect Prev, 2001, 25(2): 210-215

[41] Jong R, Davis AM, Mendes MG, et al.. Proliferative activity (ki-67 expression) and outcome in high grade osteosarcoma: a study of 27 cases. Sarcoma, 2000, 4(1–2): 47-55

[42] Marinho LC, Patricio F, Filho R-G, et al.. Clinicopathologic study and Ki-67 proliferative marker evaluation in human osteosarcomas. J Bras Patol Med Lab, 2005, 41(6): 419-424

[43] Robl B, Pauli C, Botter SM, et al.. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy. BMC Cancer, 2015, 15: 379

[44] Scotlandi K, Serra M, Manara MC, et al.. Clinical relevance of Ki-67 expression in bone tumors. Cancer, 1995, 75(3): 806-814

[45] Sorensen FB, Jensen K, Vaeth M, et al.. Immunohistochemical Estimates of Angiogenesis, Proliferative Activity, p53 Expression, and Multiple Drug Resistance Have No Prognostic Impact in Osteosarcoma: A Comparative Clinicopathological Investigation. Sarcoma, 2008, 2008: 874075

[46] Orsó E, Schmitz G. Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies. Clin Res Cardiol Suppl, 2017, 12(Suppl1): 31-37

[47] Li G, Da M, Zhang W, et al.. Alteration of serum lipid profile and its prognostic value in head and neck squamous cell carcinoma. J Oral Pathol Med, 2016, 45(3): 167-172

[48] Mieno MN, Sawabe M, Tanaka N, et al.. Significant association between hypolipoproteinemia(a) and lifetime risk of cancer: an autopsy study from a community-based Geriatric Hospital. Cancer Epidemiol, 2014, 38(5): 550-555

[49] Butler L, Perone Y, Dehairs J, et al.. Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention. Adv Drug Deliv Rev, 2020, 159: 245-293